{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:25:32Z","timestamp":1784287532448,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117040","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T21:44:45Z","timestamp":1731102285000},"page":"117040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis"],"prefix":"10.1016","volume":"282","author":[{"given":"Henry","family":"Danahay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan A.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Went","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Marlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Hewison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Kennet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lightowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Collingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117040_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatments for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2024.117040_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117040_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-obstructive lung diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117040_bib4","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2024.117040_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01297-2018","article-title":"Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH","volume":"52","author":"Hill","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2024.117040_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for the treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117040_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2024.117040_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM199907153410304","article-title":"Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism","volume":"341","author":"Kerem","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117040_bib9","first-page":"319","article-title":"Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibrosis","volume":"146","author":"K\u00f6hler","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"key":"10.1016\/j.ejmech.2024.117040_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/ajrccm\/141.3.605","article-title":"Acute and long term amiloride inhalation in cystic fibrosis lung disease: a rational approach to therapy","volume":"141","author":"App","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejmech.2024.117040_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM199004263221704","article-title":"A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis","volume":"322","author":"Knowles","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117040_bib12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1378\/chest.112.5.1283","article-title":"Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways","volume":"112","author":"Noone","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2024.117040_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2024.117040_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug induced hyperkalaemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2024.117040_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jcf.2022.02.010","article-title":"AZD5634, am inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis","volume":"21","author":"Kristensson","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2024.117040_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1183\/23120541.00429-2020","article-title":"Preclinical evaluation of the epithelial sodium channel inhibitor BI1265162 for the treatment of cystic fibrosis","volume":"6","author":"Nickolaus","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2024.117040_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117040_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1569-1993(19)30247-4","article-title":"A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies","volume":"18","author":"Danahay","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2024.117040_bib19","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.117040_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1085\/jgp.109.1.15","article-title":"Identification of amino acid residues in the alpha, beta and gamma subunits of the epithelial sodium channel (ENaC) involved in amiloride block and ion permeation","volume":"109","author":"Schild","year":"1997","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2024.117040_bib21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1124\/mol.64.4.848","article-title":"Mutations in the epithelial Na+ channel ENaC outer pore disrupt amiloride block by increasing its dissociation rate","volume":"64","author":"Kellenberger","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117040_bib22","doi-asserted-by":"crossref","first-page":"26206","DOI":"10.1074\/jbc.M503500200","article-title":"On the interaction between amiloride and its putative \u03b1-subunit epithelial Na+ channel binding site","volume":"280","author":"Kashlan","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117040_bib23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jps.10386","article-title":"Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs","volume":"92","author":"Tronde","year":"2003","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.117040_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.drudis.2021.09.005","article-title":"Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective","volume":"27","author":"Pasqua","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.117040_bib25","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm051134w","article-title":"Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis","volume":"49","author":"Hirsh","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117040_bib26","unstructured":"G. Bhalay, L. Edwards, C. Howsham, P. Hunt, N. Smith, Preparation of Pyrazine Derivatives as Epithelial Sodium Channel Blockers, Patent WO2012035158, March 22, 2012."},{"key":"10.1016\/j.ejmech.2024.117040_bib27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bmcl.2011.12.016","article-title":"Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines","volume":"22","author":"Hunt","year":"2012","journal-title":"Biorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117040_bib28","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.bmcl.2012.02.067","article-title":"Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: \u03b1-Branched quaternary amines","volume":"22","author":"Hunt","year":"2012","journal-title":"Biorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117040_bib29a","series-title":"Patent WO2011079087, 30 June","article-title":"Preparation of benzimidazole derivatives as epithelial sodium channels","author":"Laine","year":"2011"},{"key":"10.1016\/j.ejmech.2024.117040_bib29b","series-title":"Patent WO2015007516","author":"Kley","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117040_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01868737","article-title":"Structure-activity relationship of amiloride analogs as blockers of epithelial Na channels: I. Pyrazine-ring modifications","volume":"83","author":"Li","year":"1985","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.ejmech.2024.117040_bib31","unstructured":"A. Heckel, S. Frattini, D. Hamprecht, J. Kley, D. Wiedenmayer, Preparation of annelated benzamide compositions for blocking epithelial sodium channels and treatment of COPD and other pulmonary disorders, Patent WO2017028926, February 23, 2017."},{"key":"10.1016\/j.ejmech.2024.117040_bib32","unstructured":"A. Heckel, S. Frattini, D. Hamprecht, J. Kley, D. Wiedenmayer, Preparation of Annelated Phenoxyacetamides as ENaC Inhibitors, Patent WO2017028927, February 23, 2017."},{"key":"10.1016\/j.ejmech.2024.117040_bib33","series-title":"BI1265162 \u2013 Boehringer Ingelheim Inhaled ENAc Inhibitor. European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry","author":"Kley","year":"2021"},{"key":"10.1016\/j.ejmech.2024.117040_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116038","article-title":"Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis","volume":"265","author":"Betzemeier","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117040_bib35","unstructured":"C. McCarthy, J.D. Hargrave, D.A. Hay, T.B. Schofield, N. Went, Benzodiazolium Compounds as ENaC Inhibitors, Patent WO2018, 028927, May 31, 2018."},{"key":"10.1016\/j.ejmech.2024.117040_bib36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.13075","article-title":"NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia","volume":"172","author":"Coote","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117040_bib37","series-title":"ETD001: A Novel Inhaled ENaC Blocker with an Extended Duration of Action in Vivo J","author":"Danahay","year":"2024"},{"issue":"Suppl 66","key":"10.1016\/j.ejmech.2024.117040_bib38","first-page":"4338","article-title":"ETD001: a long-acting inhaled ENaC blocker, is well tolerated in humans","volume":"20","author":"Russell","year":"2022","journal-title":"Eur. Res J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342400922X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342400922X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:17:17Z","timestamp":1733516237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342400922X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S022352342400922X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117040","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Enterprise Therapeutics Limited. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117040"}}